FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The risk of cancer is decreased by following international health recommendations.

2.

Resection for Early Liver Cancer Tied to Improved Survival.

3.

Healthcare in the Mix in President Biden's Farewell Address

4.

According to new studies, some cancer patients can safely forego radiation therapy.

5.

Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot